← Back to Search

GLP-1 Agonist

GLP-1 for Low Blood Sugar

Q: Is this research experiment still accepting volunteers?

Clinicialtrials.gov's records suggest that this clinical trial is not in the process of recruitment at present. It was first listed on July 1st 2013 and has since been updated as recently as April 8th 2022, yet it does not seem to be currently seeking participants. However, there are 947 other trials searching for suitable volunteers at the moment.

Q: Is there an opportunity for me to join this medical experiment?

This clinical trial seeks 28 participants with <a href="https://www.withpower.com/clinical-trials/type-2-diabetes">type 2 diabetes</a> mellitus aged 18 to 45. The eligibility criteria are as follows: no tissue complications related to the condition, 14 healthy controls aged between 30 and 60 years of age (7 males, 7 females), 14 individuals diagnosed with Type 2 DM also in this same age range (again 7 males, 7 females) whose HbA1c levels measure 6-10%, and a BMI above 25kg/m2 for those suffering from Type 2 DM.

Q: Does the age of applicants for this research study cap at eighty years?

The parameters for this trial necessitate that those applying are between 18 and 45 years old. Conversely, 65 studies exist exclusively for the underage cohort and 790 trials can be accessed by seniors.

Phase < 1

Waitlist Available

Led By Stephen N Davis, MBBS

Research Sponsored by University of Maryland, Baltimore

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

14 (7 males, 7 females) healthy controls age 30-60 yr.

No significant diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc.)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline and end of clamp

Awards & highlights

Study Summary

This trial will help researchers learn if a hormone can help mitigate the effects of low blood sugar on blood vessels, which could help reduce the risk for heart attacks and strokes.

Who is the study for?

This trial is for adults aged 30-60 with Type 2 Diabetes who have a body mass index over 25 and controlled blood sugar levels (HbA1c between 6-10%). It's also open to healthy individuals in the same age range. People with significant diabetic complications like retinopathy or neuropathy can't participate.Check my eligibility

What is being tested?

The study is testing whether GLP-1, a hormone that occurs naturally in the gut, can reduce negative effects of low blood sugar on blood vessels. Participants will receive either GLP-1 infusion or saline as a placebo to compare outcomes.See study design

What are the potential side effects?

Possible side effects from GLP-1 may include nausea, vomiting, diarrhea, abdominal pain, and potential allergic reactions. The saline placebo is unlikely to cause any direct side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a healthy individual aged 30-60.

Select...

I do not have major complications from diabetes like eye or nerve damage.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline to end of clamp period

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline to end of clamp period

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to end of clamp period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Flow mediated dilation (FMD)

Change in Plasminogen Activation inhibitor-1 (PAi-1)

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Glucagon-Like Peptide -1 (GLP-1) infusionActive Control1 Intervention

Infusion of GLP-1 during experimental period

Group II: Saline InfusionPlacebo Group1 Intervention

Saline infusion during experimental period

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor

687 Previous Clinical Trials

374,618 Total Patients Enrolled

Stephen N Davis, MBBSPrincipal InvestigatorUniversity of Maryland, Baltimore

3 Previous Clinical Trials

60 Total Patients Enrolled

Media Library

Glucagon-Like Peptide-1 (GLP-1) (GLP-1 Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT01858896 — Phase < 1

Type 2 Diabetes Research Study Groups: Glucagon-Like Peptide -1 (GLP-1) infusion, Saline Infusion

Type 2 Diabetes Clinical Trial 2023: Glucagon-Like Peptide-1 (GLP-1) Highlights & Side Effects. Trial Name: NCT01858896 — Phase < 1

Glucagon-Like Peptide-1 (GLP-1) (GLP-1 Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01858896 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research experiment still accepting volunteers?

"Clinicialtrials.gov's records suggest that this clinical trial is not in the process of recruitment at present. It was first listed on July 1st 2013 and has since been updated as recently as April 8th 2022, yet it does not seem to be currently seeking participants. However, there are 947 other trials searching for suitable volunteers at the moment."

Answered by AI

Is there an opportunity for me to join this medical experiment?

"This clinical trial seeks 28 participants with type 2 diabetes mellitus aged 18 to 45. The eligibility criteria are as follows: no tissue complications related to the condition, 14 healthy controls aged between 30 and 60 years of age (7 males, 7 females), 14 individuals diagnosed with Type 2 DM also in this same age range (again 7 males, 7 females) whose HbA1c levels measure 6-10%, and a BMI above 25kg/m2 for those suffering from Type 2 DM."

Answered by AI

Does the age of applicants for this research study cap at eighty years?

"The parameters for this trial necessitate that those applying are between 18 and 45 years old. Conversely, 65 studies exist exclusively for the underage cohort and 790 trials can be accessed by seniors."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

GLP-1 and Hypoglycemia

Stephen N. Davis, MBBS 2013. "GLP-1 and Hypoglycemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01858896.

All > Hypoglycemia